BIOTECH-FUNDAMENTALS5 MIN READ
Call the IND readiness gap
Identify the strongest IND readiness response when nonclinical, CMC, or protocol evidence is incomplete.
The package has GLP tox and a clinical protocol, but drug product stability data do not cover the planned clinic-use window.
Read the full lesson
Sign up free — one personalized lesson every day, matched to your role and goals.
Already have an account? Sign in